Clinical Trial Update: Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating GM-CSF (sargramostim) for Down syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• sargramostim (sargramostim)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Down Syndrome | Phase 2 | Status: WITHDRAWN